Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 608-554-0 | CAS number: 3090-56-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral LD50 for the test substance was determined to be ca. 3.0 mL/kg (ca. 3200 mg/kg) in rats.
The acute inhalation LD50 for the test substance as saturated atmosphere was determined to be > 1.14 mg/L in rats.
The acute LD50 after intraperitoneal application of the test substance was determined to be ca. 0.57 mL/kg (ca. 608 mg/kg) in mice.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1967-09-26/27 and 1967-10-02
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- yes
- Remarks:
- Please refer to "Principles of method"
- Principles of method if other than guideline:
- according to BASF-internal standard
- GLP compliance:
- no
- Limit test:
- no
- Specific details on test material used for the study:
- No specific details for test material were provided.
- Species:
- rat
- Strain:
- other: US
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- No details were provided.
- Route of administration:
- oral: gavage
- Vehicle:
- other: water emulsion containing Traganth
- Details on oral exposure:
- - Application form: emulsion
- Concentration in vehicle: 2, 20 and 30 % (v/v) - Doses:
- 0.2, 1.6, 2.5 and 3.2 mL/kg bw
213.38, 1707.04, 2667.25 and 3414.08 mg/kg bw (calculated from mL/kg with a density of 1.0669 g/cm^3) - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs - Statistics:
- No statistical analysis was performed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 3 mL/kg bw
- Based on:
- test mat.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 3 200.7 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: calculated from mL/kg with a density of 1.0669 g/cm^3
- Mortality:
- 3.2 mL/kg bw: 6 animals died within 24 h after application. 1 animal died between 24 and 48 h after application.
2.5 mL/kg bw: 2 animals died within 48 h after application. 1 animal died between 48 h and 7 days after application.
1.6 mL/kg: 1 animal died between 48 h and 7 days after application.
No further mortality was observed. - Clinical signs:
- 3.2 mL/kg: ventral/side position, dyspnea, apathy, anesthetic like behavior, slack body tonus, striking blood flow in extremities, ears, nose and lips, secretion from nose. All symptoms lasted 2 days, gradually improved and were not detected in survivors from day 5 onward.
2500 cmm/kg: Belly/side position, difficult breathing and apathy was detected directly after application. After 24 h eyes were clotted and the nose was encrusted with blood. Symptoms lasted 1 day, gradually improved and were not detected in survivors from day 4 onward.
1.6 mL/kg: Staggering walk, increased breathing rate, pilo erection, hunched position, apathy was observed for over 1 day. After 2 days symptoms nearly disappeared.
0.2 cmm/kg: Staggering walk, increased breathing rate and pilo erection was observed for over 1 day. After 2 days symptoms nearly disappeared. - Body weight:
- Body weights were only determined before treatment.
- Gross pathology:
- 3.2 mL/kg: 1x blood encrusted nose, 1x chronic bronchitis
2.5 mL/kg: 2x blood encrusted nose, 1x dubiose fatty liver, 1x chronic bronchitis
No other observations were made in survivors or animals that died after treatment. - Other findings:
- No other observations were made.
- Interpretation of results:
- GHS criteria not met
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 3 200 mg/kg bw
- Quality of whole database:
- The study was conducted comparable to guideline with sufficient documentation.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1967-09-25 to 1967-10-03
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- yes
- Remarks:
- Please refer to "Principles of method"
- Principles of method if other than guideline:
- according to BASF-internal standard
- GLP compliance:
- no
- Limit test:
- no
- Specific details on test material used for the study:
- No specific details for test material were provided.
- Species:
- rat
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- No details were provided.
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- not specified
- Vehicle:
- air
- Remark on MMAD/GSD:
- No details were provided.
- Details on inhalation exposure:
- 200 L air/ h were run through a 5 cm thick layer of the test substance. The atmosphere temperature was 20 °C. The atmosphere was saturated with vapour.
- Analytical verification of test atmosphere concentrations:
- no
- Duration of exposure:
- 8 h
- Concentrations:
- 1.14 mg/L = 263 ppm (calculated from the amount of test substance weight loss during exposure)
- No. of animals per sex per dose:
- 2 runs with each 6 animals, no details on sex distribution were provided.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Frequency of observations and weighing: No details on observation intervals provided. Animals were weighted before treatment and before sacrifice.
- Necropsy of survivors performed: yes - Statistics:
- No statistical analysis was performed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC0
- Effect level:
- 1.14 mg/L air (nominal)
- Based on:
- test mat. (dissolved fraction)
- Exp. duration:
- 8 h
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 1.14 mg/L air (nominal)
- Based on:
- test mat. (dissolved fraction)
- Exp. duration:
- 8 h
- Mortality:
- No mortatity was observed.
- Clinical signs:
- other: No clinical signs were detected.
- Body weight:
- Mean body weight before treatment was 1225 g (1. group) and 1180 g (2. group).
Mean body weight after 7 days of observation was 1250 g (1. group) and 1300 g (2. group). - Gross pathology:
- No changes were detected.
- Interpretation of results:
- GHS criteria not met
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 1 140 mg/m³
- Quality of whole database:
- The study was conducted comparable to guideline with sufficient documentation.
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute toxicity
Oral
A study was conducted similar to the OECD 401 guideline. The test substance was orally administered to male and female rats in an emulsion. Each 10 animals were treated with concentrations of 0.2, 1.6, 2.5 and 3.2 mL/kg. Afterwards the animals were observed for 7 days. Several clinical symptoms were observed in increasing intensity with increasing dose. During the observation period 7 animals died after receiving 3.2 mL/kg, 3 treated with 2.5 mL/kg and one animal treated with 1.6 mL/kg. Therefore a LD50 of ca. 3.0 mL/kg was determined which corresponds to a calculated concentration of ca. 3200 mg/kg based on test substance density.
Inhalation
A study was conducted similar to the OECD 403 guideline. 200 L air/ h were run through a 5 cm thick layer of the test substance at atmosphere temperature of 20 °C. The atmosphere was saturated with vapour and the calculated concentration, based on substance weight loss, was 1.14 mg/L air. 2 independent groups of each 6 rats were exposed for 8 h. Afterwards the animals were observed for 7 days. No mortality, clinical symptoms or pathological changes were detected. Therefore a LD50 of > 1.14 mg/L was determined for the saturated atmosphere. As the atmosphere was saturated, no concentration exceeding the evaluated test substance concentration will be reached and no further effects will be expected, therefore the test substance does not need to be classified.
Intraperitoneal application
A non-guideline study was conducted in mice. The test substance was administered intraperitoneal in concentrations of 0.2, 0.4, 0.5, 0.64, 0.8 and 1.6 mL/kg to 10 mice each. Afterwards the animals were observed for 7 days. Several clinical symptoms were observed. During the observation period 10 animals died after receiving 1.6 and 0.8 mL/kg and 9 after 0.64 mL/kg. Therefore a LD50 of ca. 0.57 mL/kg was determined which corresponds to a calculated concentration of ca. 608 mg/kg based on test substance density.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008, as amended for the eighth time in Regulation (EU) No 2016/218. As a result the substance is considered to be not classified for acute oral and inhalation toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.